<DOC>
	<DOC>NCT02197975</DOC>
	<brief_summary>Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days.</brief_summary>
	<brief_title>Randomized, Crossover Safety and Pharmacokinetics Study of PT010</brief_title>
	<detailed_description>This is a Phase I, single-center, randomized, double-blind, placebo-controlled, two period, ascending dose, cross-over study to assess safety and PK of two doses of PT010 in healthy adult subjects of Japanese descent. Safety and PK will be assessed following a single dose and during twice-daily (BID) chronic dosing for 7 days.</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Informed Consent Form (ICF) prior to any study related procedures Male and female subjects first generation Japanese subjects 18 to 55 years, inclusive Body weight â‰¥50 kg (110 lbs) at the Screening Visit and body mass index between 18.5 and 32 kg/m2, inclusive Good general health Medically acceptable contraception for women of childbearing potential and males with female partners of childbearing potential Clinical labs within normal ranges or determined to be not clinically significant by the Investigator Pregnancy, nursing female subjects, or subjects trying to conceive Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study History of ECG abnormalities Cancer not in complete remission for at least 5 years Clinically significant, symptomatic prostatic hypertrophy Male subjects with a transurethral resection of the prostate or full resection of the prostate within 6 months prior to Screening Clinically significant bladder neck obstruction or urinary retention Inadequately treated glaucoma History of an allergic reaction or hypersensitivity to any drug or to any component of the formulations used in this study Subjects with preexisting anemia and/or iron deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>